Compare Citius Pharmaceuticals Inc (CTXR) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Li Auto Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while Li Auto Inc trades at $11.35 (market cap $10.83B). The key difference: Li Auto Inc is far larger — about 785.4× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (156,684 versus 2,002,427). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Li Auto Inc for 101 Days on average.
| CTXR | LI | |
|---|---|---|
Market Cap | $13.79M | $10.83B |
Volume | 156,684 | 2,002,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $23.61 |
52-Week Low | $0.48 | $10.69 |
Typical Hold Time | 16 Days | 101 Days |
Enterprise Value | $3.96M | $258.87M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
Li Auto (LI) trades at $10.90, near 52-week lows amid declining delivery volumes and negative earnings surprises. The stock shows bearish technical signals with oversold RSI levels, while fundamentals reveal revenue contraction from $144.5B (2024) to $112.3B (2025) and negative net margins. Recent vehicle launches (Li i9, MEGA) aim to counter competitive pressures in China's EV market, but cash flow trends show operational challenges with -$8.6B operating cash flow in 2025.
Outlook remains challenged by execution risks and market saturation, though analyst consensus target of $15.18 suggests 39% upside. Key risks include persistent cash burn, intense domestic competition, and macroeconomic headwinds. The valuation appears reasonable with P/S of 0.73, but profitability recovery is critical for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
